Moreover, in cancer patients with ongoing bacterial infections, the effect of ABCG2 inhibitor can be particularly detrimental, as the combination of ABCG2 inhibitor and bacterial LPS can exacerbate the immunosuppressive state, worsening both the infection and the cancer. Here, ABCG2 is linked to cancer.